DiaMedica Therapeutics Inc.
DMACHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. The company carries a $470.2M market cap, placing it firmly in the small-cap category. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Market Cap
$470.2M
Beta
0.91
P/E (TTM)
—
P/E (Fwd)
-11.67
EPS (TTM)
$-0.72
EPS (Fwd)
$-0.75
ROE
-114.6%
ROA
-64.1%
Cash
$43.5M
Total Debt
$185,000
Free CF
-$17.6M
52W Change
26.7%
Annual Financials
Cash vs Debt
Where DMAC stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, DMAC finished 14.16% above its 150-day moving average ($6.71) and 8.19% above its 200-day moving average ($7.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DMAC overbought or oversold?
At the October 15, 2026 close, DMAC's RSI(14) was 46.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $43.5M in cash and $185K in debt, DMAC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$17.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -114.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for DiaMedica Therapeutics Inc. and its sector.